PMID- 35988189
OWN - NLM
STAT- MEDLINE
DCOM- 20220823
LR  - 20220901
IS  - 1165-158X (Electronic)
IS  - 0145-5680 (Linking)
VI  - 68
IP  - 3
DP  - 2022 Mar 31
TI  - The Intervention of Nano-targeted Drugs & Angioplastryin Treatment and Prevention 
      of Vascular Restenosis and its Influence on Monocyte Chemotactic Protein-1 in 
      Lower Extremity Angiopathy.
PG  - 347-355
LID - 10.14715/cmb/2022.68.3.38 [doi]
AB  - It was to make use of the nano-targeted drugs and angioplastry to treat and 
      prevent the vascular restenosis and analyze its influence on monocyte chemotactic 
      protein 1 (MCP-1) of lower extremity angiopathy (LEA) patients since the patients 
      with diabetic lower extremity angiopathy may be easily infected with vascular 
      restenosis. In this article, the dexamethasone nano drugs were firstly prepared. 
      After that, its related physical and chemical properties were tested, then, 
      dexamethasone nano drugs were applied in treating patients with diabetic lower 
      extremity angiopathy. The results showed that the prepared dexamethasone 
      nanoparticles' encapsulation rate attained 99.2%. The laser light scattering 
      experiment manifested that the particle size of the nanoparticles ranged from 200 
      to 300nm, and the average particle size was 258nm. The MCP-1 of the control 
      group, conventional group, and observation group were 33.28+/-1.93 microg/mL, 
      78.27+/-9.73 microg/mL, and 75.29+/-8.99 microg/mL, respectively. The MCP-1 values of the 
      conventional and observation groups were higher than that of the control group, 
      and there was a notable difference (P<0.05). After interventional treatment, the 
      MCP-1 level of the conventional group was 57.82+/-5.82 microg/mL, and that of the 
      observation group was 41.93+/-6.92 microg/mL. The MCP-1 level of the group which 
      received the treatment of nano-targeted drugs and angioplastry was superior to 
      that of the conventional group which received the traditional operation, and 
      there was a notable difference (P<0.05). In conclusion, MCP-1 is one of the major 
      causes of lower extremity angiopathy. The nano-targeted drugs and angioplastry 
      can raise the expression level of MCP-1 in patients with lower extremity 
      angiopathy. The experimental results had a high application value and the 
      nano-targeted drugs & angioplastry can be promoted clinically.
FAU - Ji, Kun
AU  - Ji K
AD  - Department of General Surgery, Tongji Hospital, School of Medicine, Tongji 
      University Medicine School, 389 Xincun Road, Shanghai, 200065, China. 
      jkll0808@163.com.
FAU - Zhang, Yaming
AU  - Zhang Y
AD  - Department of General Surgery, Tongji Hospital, School of Medicine, Tongji 
      University Medicine School, 389 Xincun Road, Shanghai, 200065, China. 
      jkll0808@163.com.
FAU - Huang, Daojing
AU  - Huang D
AD  - Department of General Surgery, Tongji Hospital, School of Medicine, Tongji 
      University Medicine School, 389 Xincun Road, Shanghai, 200065, China. 
      jkll0808@163.com.
LA  - eng
PT  - Journal Article
DEP - 20220331
PL  - France
TA  - Cell Mol Biol (Noisy-le-grand)
JT  - Cellular and molecular biology (Noisy-le-Grand, France)
JID - 9216789
RN  - 0 (Chemokine CCL2)
RN  - 0 (Nanoparticle Drug Delivery System)
RN  - 7S5I7G3JQL (Dexamethasone)
SB  - IM
MH  - *Angioplasty/methods
MH  - Chemokine CCL2/metabolism
MH  - Constriction, Pathologic
MH  - Dexamethasone
MH  - *Diabetic Angiopathies/drug therapy/therapy
MH  - Humans
MH  - Lower Extremity
MH  - *Nanoparticle Drug Delivery System/pharmacology/therapeutic use
MH  - Nanoparticles/therapeutic use
MH  - *Peripheral Vascular Diseases/drug therapy/therapy
EDAT- 2022/08/22 06:00
MHDA- 2022/08/24 06:00
CRDT- 2022/08/21 14:36
PHST- 2022/04/25 00:00 [received]
PHST- 2022/08/21 14:36 [entrez]
PHST- 2022/08/22 06:00 [pubmed]
PHST- 2022/08/24 06:00 [medline]
AID - 10.14715/cmb/2022.68.3.38 [doi]
PST - epublish
SO  - Cell Mol Biol (Noisy-le-grand). 2022 Mar 31;68(3):347-355. doi: 
      10.14715/cmb/2022.68.3.38.